SRZNSurrozen, Inc./DE同业对比
Surrozen, Inc./DE 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRZN本股 | $363M#8 | — | — | 104.3x#8 | -67.4%#8 | -280.8%#14 | -1210.6%#7 | — | — | — | 120.4%#2 | — |
| GRML | $626M#1 | — | 10.8x#12 | — | — | -71.6%#12 | — | -18.2%#4 | -14.6%#2 | — | -83.3%#14 | — |
| RGNX | $517M#2 | — | 7.2x#11 | 3.0x#3 | 104.5%#3 | 14.6%#6 | -94.6%#3 | -270.2%#11 | — | — | -32.1%#12 | — |
| EDIT | $418M#3 | — | 4.0x#10 | 10.3x#5 | 25.4%#4 | 32.5%#4 | -394.9%#6 | -152.0%#10 | — | — | -1.8%#9 | — |
| ALLO | $406M#4 | — | 0.9x#2 | — | -100.0%#9 | 25.9%#5 | — | -43.8%#6 | — | — | 7.3%#7 | — |
| ZURA | $386M#5 | — | 3.8x#9 | — | — | -31.0%#11 | — | -67.6%#8 | — | — | 16.4%#6 | — |
| TECX | $382M#6 | — | 1.7x#6 | — | — | -27.9%#10 | — | -33125.9%#12 | -713.5%#5 | — | 16.4%#5 | — |
| CCCC | $378M#7 | — | 1.5x#5 | 10.5x#6 | 1.0%#7 | 0.3%#7 | -320.5%#5 | -42.5%#5 | — | — | 36.4%#4 | — |
| KYTX | $322M#9 | — | 1.9x#7 | — | — | -26.5%#9 | — | -97.4%#9 | -107.1%#3 | — | -17.9%#10 | — |
| SCTX | $311M#14 | — | — | — | — | — | — | — | — | — | — | — |
| AGEN | $314M#11 | 2.3x#2 | — | 2.7x#1 | 10.4%#5 | 98.7%#2 | -17.7%#2 | — | — | — | 86.9%#3 | — |
| XFOR | $316M#10 | 2.2x#1 | 2.0x#8 | 9.0x#4 | 1273.2%#2 | -111.5%#13 | -247.4%#4 | -50.9%#7 | -582.0%#4 | — | -19.2%#11 | — |
| SABS | $300M#15 | 13.8x#3 | 1.4x#4 | — | -100.0%#9 | 138.9%#1 | — | 6.2%#1 | — | — | 1.5%#8 | — |
| IPSC | $313M#12 | — | 1.3x#3 | 2.9x#2 | 1556.8%#1 | 92.4%#3 | -15.8%#1 | -4.1%#3 | -9.3%#1 | — | 203.4%#1 | — |
| EIKN | $313M#13 | — | 0.7x#1 | — | — | — | — | 0.0%#2 | — | — | — | — |
| OCGN | $300M#16 | — | — | 67.9x#7 | 8.8%#6 | -25.9%#8 | -1425.7%#8 | — | — | — | -38.0%#13 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议